Longevity Lab
NR supplement fails to slow Parkinson’s disease in major trial
Olivia Gagnon · October 10, 2026
An NR supplement failed to slow Parkinson's disease progression in a major Phase III trial, according to JAMA research.
01
03
04
05
An NR supplement failed to slow Parkinson's disease progression in a major Phase III trial, according to JAMA research.
An NR supplement failed to slow Parkinson's disease progression in a major Phase III trial, according to JAMA…
CRISPR HAE therapy by Intellia may receive FDA approval in March 2027, offering a one-time treatment to lower…
The enzyme FAH may predict resistance to CDK4/6 inhibitors in hormone receptor-positive breast cancer, offering potential for better…
Scientists are exploring a way to treat fibrotic disease by reactivating a cellular process that naturally declines with…
Ultra-processed foods may alter metabolism and brain responses even with matching nutritional content, as shown in a Nature…
Scotland offers more than 250 NHS jobs parents can take, giving six-to-18-month paid placements nationwide across 18 health…
The UK pest control industry handles over 4.4 million client jobs annually and prevents economic losses worth £1.9…
Public sector buildings require skilled contractors to mitigate electrical risks for students, patients, and visitors—ensuring compliance and real-time…
Clear signage in public spaces is key to trust and safety, experts say, as effective wayfinding design guides…
Scotland bans junk food displays in supermarkets to reduce unhealthy choices, affecting stores with over 50 employees starting…
